Does Doxylamine-Pyridoxine for Nausea in Pregnancy Actually Work?
BACKGROUND AND PURPOSE:
Doxylamine-pyridoxine is a first-line treatment for nausea during pregnancy
Well-designed studies for medications to treat nausea and vomiting in pregnancy are limited
One published RCT (see ‘Learn More – Primary Sources’ below), known as DIC-301, is the basis for the FDA approval as well as positive guideline recommendations
Meaney et al. (Plos one, 2018) reanalyzed unpublished DIC-301 methods and results data that had been submitted to Health Canada
Authors re-analyzed individual level data from the DIC-301 RCT
The timing of primary outcome ascertainment, the analysis plan for the primary outcome, the secondary outcomes, and the sample size justification were changed after the study was completed
Unclear if changes to the analysis plan were made prior to or after initiating analysis
DIC-301: Randomized controlled trial (RCT)
Pregnant women between 7 and 14 weeks of gestation
Moderate nausea and vomiting during pregnancy
Women were randomized to take either
One tablet doxylamine 10 mg/pyridoxine 10 mg between 2 and 4 times per day for 14 days depending on symptoms
An identical placebo tablet taken using the same instructions
The primary outcome was improvement in nausea and vomiting of symptoms scores using the 13-point pregnancy unique quantification of emesis (PUQE) scale between baseline and 14 days
Prespecified minimal clinically important difference was defined as an “expected difference” of 3 points
Data for 131 active treatment participants and 125 control participants were analyzed
On the final day of the trial, 101 active treatment participants and 86 control participants provided primary outcome measures
There was greater improvement in symptoms scores with doxylamine-pyridoxine compared with placebo (0.73 points; 95% CI 0.21 to 1.25), but only when ‘last observation carried forward imputation’ was used to populate missing values with the subject’s previous non-missing values
When using any other methods to deal with missing data, there was no statistical difference
Doxylamine-pyridoxine trended toward efficacy, but depends on how missing data is evaluated
Even if statistically significant, the authors did not find a clinically significant difference meeting the prespecified threshold
The FDA statistical review of the DIC-301 accepted the difference between groups of 0.73 from the ‘last carried forward imputation’ methodology
The FDA summary stated that there was a “small, but statistically significant improvement” and “although the treatment effect is small, there are no other FDA-approved treatments for nausea and vomiting of pregnancy”
The authors suggest that due to small clinical impact and the fact that this trend is only seen if using one particular approach to dealing with missing data, recommendation for first-line usage of doxylamine-pyridoxine should be reevaluated
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan